Highbridge Capital Management’s Cytokinetics CYTK Stock Holding History

Highbridge Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,910	Closed	-$314K	–	1570
2017 Q2	$314K	Buy	+25,910	New	+$360K	﹤0.01%	951
2016 Q4	–	Sell	-59,075	Closed	-$543K	–	1310
2016 Q3	$543K	Buy	+59,075	New	+$617K	0.01%	754
2016 Q1	–	Sell	-75,874	Closed	-$793K	–	1542
2015 Q4	$793K	Buy	+75,874	New	+$744K	0.01%	836
2015 Q2	–	Sell	-110,169	Closed	-$746K	–	1451
2015 Q1	$746K	Buy	110,169 +93,367	+556%	+$697K	0.01%	844
2014 Q4	$135K	Sell	16,802 -105,430	-86%	-$452K	﹤0.01%	1093
2014 Q3	$431K	Buy	122,232 +98,738	+420%	+$415K	0.01%	892
2014 Q2	$112K	Buy	+23,494	New	+$143K	﹤0.01%	1002
2014 Q1	–	Sell	-22,639	Closed	-$148K	–	1087
2013 Q4	$148K	Sell	22,639 -22,397	-50%	-$147K	﹤0.01%	990
2013 Q3	$342K	Buy	45,036 +30,588	+212%	+$328K	﹤0.01%	999
2013 Q2	$167K	Buy	+14,448	New	+$114K	﹤0.01%	1207

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Highbridge Capital Management's CYTK Position: Q3 2017 in Review

Highbridge Capital Management sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 25,910 shares — an estimated $314K sold.

Highbridge Capital Management first reported a position in CYTK in Q2 2013 and held it in 10 quarters. The position peaked at $793K in Q4 2015. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

Highbridge Capital Management reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 25,910 Cytokinetics shares in Q3 2017, an estimated $314K.
Highbridge Capital Management first reported a position in Cytokinetics in Q2 2013 and held it in 10 quarters.
Highbridge Capital Management's Cytokinetics position peaked at $793K in Q4 2015.
132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.